Status:
UNKNOWN
Study of Carboplatin/Gemcitabine Plus Bevacizumab in Advanced Lung Cancer
Lead Sponsor:
St. John Providence Health System
Collaborating Sponsors:
Genentech, Inc.
Eli Lilly and Company
Conditions:
Non-Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
* this study is being done to find out if the combination of carboplatin and gemcitabine will be more effective in the the treatment of advanced lung cancer if bevacizumab, an agent that blocks tumor ...
Detailed Description
* Patients with advanced (stage IV, and Stage IIIB with effusion) non-small cell lung cancer with non-squamous histology, good performance status, and adequate organ function are eligible. * Patients ...
Eligibility Criteria
Inclusion
- Histologically or cytologically proven non-small cell lung cancer, newly diagnosed or recurrent after previous surgery and/or radiation therapy
- Stage IV disease or stage IIIB with a malignant pleural effusion
- measurable or evaluable disease
- Performance status 0 or 1 (ECOG)
- adequate renal, hepatic, and bone marrow function
- adequate recovery from previous surgery or radiotherapy
- informed consent
Exclusion
- brain metastases
- squamous (epidermoid) histology
- hemoptysis
- central airway disease
- Pancoast tumors
- previous chemotherapy or biologic therapy for lung cancer
- prior malignancy within the previous 5 years except non-melanoma skin cancer or cervical CIS
- pregnant or nursing women
Key Trial Info
Start Date :
November 1 2004
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT00150657
Start Date
November 1 2004
Last Update
November 29 2005
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Providence Cancer Institute
Southfield, Michigan, United States, 48075